TGS – Genomic analysis for Assessing TB infections

About TGS

A WGS product for TB assessment

WGS

Tuberculosis (TB) continues to be a major public health issue. Patients with Drug Resistance  such as multidrug resistance (MDR) or extremely drug resistant (XDR) TB show lower rates of treatment success as well, being 50% and 30% for each category, respectively.  One of the main criteria to treating TB patients successfully, is to administer the right treatment early. Whole genome sequencing (WGS) is a technique that can be used to rapidly diagnose DR-TB by providing rapid, detailed and information for multiple gene regions across the whole TB genome. This approach overcomes many challenges associated with conventional phenotypic testing as well as the limitations of other less comprehensive molecular tests.

The use of WGS has been supported by global and national authorities for its advantages. It has been successfully implemented in other countries as a tool for mass patient use.

TGS

The TGS is based on such technology. It is a WGS based test powered by the ΩTB® analytics by HaystackAnalytics Pvt. Ltd. that combines genome sequencing and analysis for a faster, more sensitive, more reliable, and cost-effective method of tuberculosis diagnosis.

Benefits for Doctors and patients

For Doctors

18 antibiotics

TGS tests for 18 antibiotics, covering all categories TB drugs including BEDAQUILINE, PRETOMANID and DELAMANID, providing a more complete visualization of resistance profiles.

Classify strains

WGS looks into the whole genome, thus enabling a strain level classification of the infecting pathogen. The phylogenetic categorization of TB is covered in the report. It can also help identify relapse or reinfections.

Mixed infections

Clinical diagnoses consider a single clone to be representative of an infection. Genomic variation between pathogens can sometimes uncover the presence multiple alleles at a single locus. In TB diagnoses such heterozygosity are of significant biological relevance, since they indicate the presence of mixed infection which can be detected.

Accuracy

Being a molecular test, it provides a high level of accuracy and with molecular tests being the method of choice in determining drug susceptibility profile across all TB drug categories.

Personalize treatment

All TGS reports contain details of drug susceptibility profiles across 18 antibiotics, mixed infections and strain identification allowing physicians to pursue highly individualized treatment regimens and reach infection control decisions quickly.

Evidence based reports

All TGS reports are evidence-based continuing information used to call resistance including gene name, variant, gene ID, antibiotics to which it imparts resistance, confidence of mutation for calling drug resistance links to peer reviewed studies demonstrating the mutation is associated with drug resistance.

Future-proofed

The analysis has a consistently updated catalog that ensures that the reporting is based on the most current available information and standards.

For Patients

Single comprehensive test

TGS is an all-in-one test that gives complete information. It covers antibiotic profile for the maximum number of drugs. Being a molecular test, it has a high accuracy permitting faster diagnosis.

Shorter testing time

Compared to current day tests, the TGS gives complete profile within 12 days hence saving previous time, that can help out patients on the right treatment early.

Cost-effective

The TGS an affordable and reliable option with a competitive price for a single comprehensive test.

For further information, please contact tgs@focustb.com or send TGS on WhatsApp at +91 9870666333

References:
  1. World health Organization. The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: Technical guide. 2018.
  2. National TB Elimination Programme. Guidelines Votintseva AA. 2017. Same-Day Diagnostic and Surveillance Data for Tuberculosis via Whole-Genome Sequencing of Direct Respiratory J Clin Mic https://doi.org/10.1128/JCM.02483-16
  3. Chatterjee A. 2017. Whole genome sequencing of clinical strains of Mycobacterium tuberculosis from Mumbai, India: A potential tool for determining drug-resistance and strain lineage. Tuberculosis (Edinb) 107:63-72. doi: 10.1016/j.tube.2017.08.002
  4. Coll F, Phelan J. 2018. Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis. Nature Genetics. 307–316. https://doi.org/10.1038/s41588-017-0029-0
  5. Lee RS, Behr MA. 2016. The implications of whole-genome sequencing in the control of tuberculosis. Ther Adv Infect Dis 3:47– 62. https://doi.org/10.1177/2049936115624630.
  6. Takiff HE, Feo O. 2015. Clinical value of whole-genome sequencing of Mycobacterium tuberculosis. Lancet Infect Dis 15:1077–1090. 1.       https://doi.org/10.1016/S1473-3099(15)00071-7.
  7. Witney AA, Cosgrove CA, Arnold A, Hinds J, Stoker NG, Butcher PD. 2016. Clinical use of whole genome sequencing for Mycobacterium tuberculosis. BMC medicine 14:46. https://doi.org/10.1186/s12916-016-0598-2.
Bitnami